Abstract
Introduction: Guselkumab (GUS) efficacy in adult patients with active PsA is evaluated through Week (W) 24 using composite indices from DISCOVER-1/DISCOVER-2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have